Add time:09/24/2019         Source:sciencedirect.com

BackgroundPreeclampsia complicates approximately 3–5% of pregnancies and remains a major cause of maternal and neonatal morbidity and mortality. It shares pathogenic similarities with adult cardiovascular disease as well as many risk factors. Pravastatin, a hydrophilic, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, has been shown in preclinical studies to reverse various pathophysiological pathways associated with preeclampsia, providing biological plausibility for its use for preeclampsia prevention. However, human trials are lacking.

We also recommend Trading Suppliers and Manufacturers of 3-Hydroxy Pravastatin (cas 136657-41-5). Pls Click Website Link as below: cas 136657-41-5 suppliers